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Abstract 1	
Dengue virus (DENV) infection causes a characteristic pathology in humans involving dysregulation of 2	
the vascular system. In some patients with dengue hemorrhagic fever (DHF), vascular pathology can 3	
become severe, resulting in extensive microvascular permeability and plasma leakage into tissues 4	
and organs. Mast cells (MCs), which line blood vessels and regulate vascular function, are able to 5	
detect DENV in vivo and promote vascular leakage. Here, we identified that a MC-derived protease, 6	
tryptase, is consequential for promoting vascular permeability during DENV infection, through 7	
inducing breakdown of endothelial cell tight junctions. Injected tryptase alone was sufficient to induce 8	
plasma loss from the circulation and hypovolemic shock in animals. A potent tryptase inhibitor, 9	
nafamostat mesylate, blocked DENV-induced vascular leakage in vivo. Importantly, in two 10	
independent human dengue cohorts, tryptase levels correlated with the grade of DHF severity. This 11	
study defines an immune mechanism by which DENV can induce vascular pathology and shock. 12	
 13	
Introduction 14	
In humans, dengue virus (DENV) causes an acute viral infection that manifests as a broad 15	
spectrum of disease: from asymptomatic infection, to a mild febrile illness, dengue fever (DF) that may 16	
resolve within 2 weeks, to the most severe form, dengue hemorrhagic fever (DHF), which involves 17	
vascular leakage as the primary potentially life-threatening sign. When homeostatic mechanisms fail, 18	
the widespread vascular leakage that occurs during DHF can also lead to dengue shock syndrome 19	
(DSS) resulting from hypovolemia (1, 2). In the initial classification scheme for DHF/DSS, patients 20	
were also graded according to severity of DHF: DHF-I involving fever accompanied with positive 21	
tourniquet test and or easy bruising, DHF-II involving spontaneous bleeding or frank hemorrhaging, 22	
DHF-III is characteristic of shock such as circulatory failure due to rapid weak pulse and narrowing of 23	
pulse pressure and DHF-IV being severe shock without a pulse that is usually fatal(3). The 24	
predominant view of the field is that vascular leakage in humans results from immune-mediated 25	
pathology rather than infection of endothelial cells themselves (2). One theory is that “cytokine storm” 26	
damages the vascular endothelium during infection. These cytokines could be derived from infected 27	
cells that contain replicating virus, or other immune cells that respond to infection such as T cells and 28	
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mast cells (MCs)(4, 5). TNF, for example, has been shown to promote vascular leakage and death 29	
due to dengue in an immunocompromised mouse model (6); however, in human patients there have 30	
been less clear associations between specific vasoactive cytokines and vascular leakage during 31	
infection and even conflicting associations in various studies (2, 7-9). If cytokine storm is involved, it is 32	
also unclear why symptoms of dengue differ from other conditions that involve cytokine storm (2). 33	
Others have identified high levels of complement activation in pediatric DSS patients(10), which could 34	
be further enhanced in the presence of NS1 protein(11). Reports suggest that NS1 alone can directly 35	
induce vascular permeability (12, 13) and there are conflicting reports regarding whether NS1 levels 36	
correlate with DENV disease severity in human studies as well as in animal models (14-18). Thus, we 37	
do not fully understand the mechanism of DENV-induced vascular leakage in humans. Even in mild 38	
dengue cases, usually diagnosed as DF, signs and symptoms of dengue vascular pathogenesis and 39	
immune activation can be present, such as bruising, purpura, petechiae, rash, and hemoconcentration 40	
(1, 2). It is also possible that the signs of vascular leakage, hemorrhaging and shock are not merely 41	
due to an augmentation of the same mechanism, but they may have independent mechanisms that 42	
contribute to the spectrum of disease. 43	
Interestingly, some clinical signs similar to those that occur as a result of DENV infection have 44	
been associated with the effects of activated MCs in independent clinical contexts, such as during 45	
allergic reactions or anaphylactic shock (19). These include signs such as vascular leakage, rash, 46	
flushing and abdominal pain(20, 21). In those allergic conditions, MC-derived products can cause 47	
urticaria, edema, vasodilation, and blood pressure changes (19). Mature MCs do not circulate in the 48	
blood but are found only in connective and mucosal tissues (22). There, they act as sentinels for 49	
pathogens, including DENV (23, 24), and also serve an immune regulatory function at tissue sites 50	
(25). In addition to their relatively even dispersal throughout the skin and mucosae, a portion of MCs 51	
also adopt a perivascular distribution in vivo (26). It has been shown in mice that MCs may even 52	
extend processes into the lumen of blood vessels(27). They store vasoactive mediators in their 53	
granules, including heparin, tryptase, chymase, additional proteases, and preformed cytokines (e.g. 54	
TNF)(26, 28). MC granules remain insoluble for hours after their release as membrane-free particles 55	
and they are thought to slowly release their cargo in the extracellular environment (29, 30). Proteases 56	
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account for the majority of the granule protein content, of which chymase and tryptase are the most 57	
abundant(28). Chymase is understood to impact the renin-angiotensin system as an Angiotensin-I to 58	
Angiotensin-II converting enzyme (31), while tryptase has primarily been characterized to play a role 59	
in vascular leakage, through its ability to cleave PAR receptors (32).  60	
 In vivo studies revealed that MCs play a key role in protective immune response involving 61	
cellular recruitment to sites of localized cutaneous DENV infection in mice (24). However, as the 62	
infection spreads and becomes systemic, the role of MCs becomes more complex (4). We previously 63	
investigated the interactions between MCs and DENV in the mouse model and determined that DENV 64	
induces MC degranulation (24). Mature MCs are highly resistant to infection and degranulation occurs 65	
independent of virus replication within MCs since UV-inactivated virus triggers a degranulation 66	
response similar to live virus(24). MCs also promoted recruitment of T and NK cells to infection sites 67	
and viral clearance through de novo chemokine production (24) and activation of cytotoxic T cells, 68	
such as γδT cells, through non-classical antigen presentation(33). Contrasting to their protective 69	
function in localized infection, widespread activation of MCs during systemic infection can contribute 70	
to DENV-induced vascular leakage in mice (34). Antibodies can also enhance the DENV-induced 71	
activation of MCs, by crosslinking of activating FcγRs, similar to the mechanism described for MC 72	
activation during the reverse arthus reaction (5, 35). In human DENV patients, detection of heightened 73	
serum protein levels of the MC-specific and granule-associated product, chymase, during the acute 74	
febrile phase of disease, indicated that MCs are activated during DENV infection(34, 36). Chymase 75	
was not elevated in the serum of other febrile patients, most of which were experiencing respiratory 76	
infections (34).  Importantly, chymase levels were higher in the serum of patients diagnosed with DHF 77	
than those diagnosed with DF during both the acute febrile (within 3 days of fever onset in that study) 78	
and defervescent phases of disease, but highest at the earliest time points, and higher in DHF/DSS 79	
patients experiencing secondary infections compared to primary infection (34). Thus, chymase levels 80	
were correlated with disease severity prior to diagnosis of severe disease, raising the possibility that 81	
chymase could serve as a prognostic biomarker for severe dengue (34, 36). Taken together, the data 82	
suggest that systemic DENV infection initiates a cascade of events involving wide-spread MC 83	
activation leading to persistent levels of MC-derived products in the serum throughout the acute 84	
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phase of disease, which damage the vascular endothelium. Yet, the mechanism by which MCs 85	
promote endothelial activation and vascular permeability during DENV infection remains unknown. In 86	
this study we sought to identify the MC mediator primarily responsible for endothelial breakdown and 87	
vascular leak during DENV disease. We show that DENV-elicited tryptase is a particularly potent 88	
inducer of microvascular permeability, which occurs mechanistically through disruption of endothelial 89	
tight junctions. Validation of these findings in mice suggest that tryptase promotes substantial 90	
increases in plasma loss from the circulation and reduced adhesion molecule expression on vascular 91	
endothelial cells, while chymase, in contrast, has a more modest effect. A potent specific inhibitor 92	
against tryptase was sufficient to reduce DENV-induced vascular leak in vivo in multiple mouse 93	
models. Remarkably, in human patients with DHF, levels of serum tryptase were highest when 94	
patients experienced shock (DHF grades III-IV), and were well correlated with the severity of DHF. 95	
These findings suggest that high levels of tryptase can cause shock during DHF. 96	
 97	
Results 98	
 99	
Mast cell proteases, tryptase and chymase, promote endothelial permeability and break tight 100	
junctions. 101	
To identify the MC-derived products that promote vascular leakage during DENV infection, we 102	
first questioned whether the soluble or particulate (exocytosed MC granules(30)) fractions were 103	
primarily responsible for inducing endothelial permeability. The soluble fraction of media after MC 104	
activation would contain the de novo synthesized products, such as eicosanoids and most cytokines, 105	
as well as pre-stored mediators that are quickly solubilized from the granule after activation, such as 106	
histamine. The particulate fraction would contain largely the insoluble pre-stored mediators, including 107	
heparin, and the proteases that make up the majority of heparin-associated proteins, including 108	
chymase and tryptase (37). These fractions were separated by centrifugation and human 109	
microvascular endothelial cells (huMECs) were cultured to form a tight monolayer followed by 110	
treatment of the monolayers with total or fractionated portions of DENV-induced MC products. The 111	
degree of damage to the endothelial integrity was determined by measuring trans-endothelial 112	
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resistance (TER). Our previous studies showed that the TER was dramatically reduced when 113	
endothelial monolayers were treated with DENV-elicited MC products compared to the control un-114	
treated groups, treatments with supernatants from mock-infected MCs or with an equivalent amount of 115	
DENV in media alone (34). Here, when DENV-elicited MC products were further separated into 116	
soluble and particulate fractions, treatment of huMEC monolayers with the particulate fraction 117	
significantly reduced the TER compared to the soluble fraction treatment group, while the same 118	
concentration of virus alone did not have a significant effect (Figure 1A). This data suggests that it is 119	
the MC granule-associated components that are important in breaking endothelial integrity. 120	
 The two dominant protein constituents of granules are the MC proteases, chymase and 121	
tryptase. We previously had determined that chymase is a biomarker of severe vascular leakage in 122	
human DENV patients (34), but whether it also has a functional role in DENV-induced vascular 123	
leakage remained unclear. In order to address the direct ability of MC proteases to induce endothelial 124	
permeability, we cloned, expressed and purified the two dominant MC proteases, both human 125	
tryptase and human chymase, as histidine-tagged recombinant proteins for use in functional assays. 126	
The proteins were chromatography purified, tested to be endotoxin free, and tested to verify for 127	
functional protease activity. Incubation of tryptase with huMECs resulted in a strong, dose-dependent 128	
increase in endothelial permeability, as demonstrated by a drop in the TER (Figure 1B). In contrast, 129	
chymase promoted only a moderate decrease in the TER of huMEC monolayers at the highest (1µM) 130	
concentration tested (Figure 1C). This data points to the role these proteases could play during DENV 131	
disease severity. 132	
Next, we sought to understand the mechanism behind tryptase/chymase-induced endothelial 133	
permeability. Since tight junctions between the cells are crucial for maintaining the endothelial barrier 134	
function and tryptase, in particular, has been described to cleave the tight junction component PAR-2 135	
(38), we questioned whether loss of tight junctions would underlie the MC-protease induced increases 136	
in endothelial permeability. To address this, huMECs were cultured to form a monolayer on glass 137	
coverslips, followed by exposing them with two different concentrations (0.1µM and 1µM) of tryptase 138	
or chymase for 24h. At 24h post-treatment, cells were fixed and immunostained for tight junction 139	
protein ZO-1 and tubulin to reveal each individual cell cytoskeleton, and with DAPI for nuclear 140	
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localization. The microscopy images show a uniform continuous staining of ZO-1 in un-treated control 141	
cells (Figure 1D), suggestive of intact endothelial tight junctions. However, treatment of huMEC 142	
monolayers with tryptase lead to dramatic damage of tight junctions, with ZO-1 staining completely 143	
disappearing at the high, 1µM concentration of tryptase (Figure 1E). Individual cells were also 144	
observed to lift from the coverslips leaving large gaps between cells (Figure 1E). This effect was 145	
substantial even with low dose tryptase treatment (0.1µM), where only punctate staining for ZO-1 at 146	
the cell borders remained (Figure 1E). Consistent with the TER data presented in Figure 1C, chymase 147	
treatment also caused damage to tight junctions but to a lesser extent compared to that of tryptase 148	
treatment (Figure 1F). Collectively these data show that both tryptase and chymase are able to break 149	
tight junctions between endothelial cells, causing increases in endothelial permeability. 150	
 151	
Tryptase treatment reduces surface expression of adhesion molecule CD31 on vascular 152	
endothelium. 153	
To understand in detail how tight junctions are affected in vivo by the MC proteases, chymase 154	
and tryptase, we measured the surface expression of cell adhesion molecule CD31 (also called 155	
PECAM-1) on vascular endothelial cells after injection of either of these proteases. For this, 100ng of 156	
tryptase or chymase was injected in the mouse rear footpad followed by harvest of the tissue from 157	
footpad after 6h. Single cell suspensions were prepared from the tissue and endothelial cells were 158	
stained using an antibody against CD31, which is both a maker for endothelial cells and a functional 159	
component of tight junctions, before being analyzed by flow cytometry. The data demonstrate that the 160	
mean fluorescence intensity (MFI) of CD31 staining was significantly decreased upon tryptase 161	
treatment compared to that of the saline injection control (Figure 1G-H). Chymase treatment, in 162	
contrast, did not influence the surface expression of CD31 (Figure 1H). In the context of DENV 163	
infection in vivo, CD31 expression was also found to be significantly reduced on endothelial cells 164	
when mice were infected with DENV (Supplemental Figure 1). These data suggest that during DENV 165	
infection, tryptase breaks tight junctions between endothelial cells and results in a reduction in the 166	
surface expression of cell-cell adhesion molecule, CD31, in vivo. In contrast, the effect of chymase 167	
was not significant after injection and did not influence CD31 expression. 168	
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 169	
MC proteases, tryptase and chymase, promote vascular leakage and induce hypovolemic 170	
shock in vivo. 171	
To determine if MC proteases could have a functional role in plasma loss during DENV 172	
infection in vivo, we injected them i.v. in mice, aiming for a final serum concentration of proteins 173	
around 10ng/mL, approximately equivalent to the concentrations of proteases that were previously 174	
reported in the serum of human DHF patients(34), assuming a ~3mL blood volume for a mouse. Mice 175	
were injected with chymase or tryptase and at 6h post-injection; hematocrit values were measured 176	
from the blood to quantify the degree of plasma loss from circulation in mice after treatments. Both 177	
chymase and tryptase were sufficient to induce physiologically significant increases in vascular 178	
leakage, which was measured as an increase in hematocrit (Figure 2A). However, tryptase resulted in 179	
a ~16% increase in the RBC volume in the blood, compared to a ~3.8% increase in RBC volume after 180	
chymase injection (Figure 2A). Injection of a control protein, ovalbumin (OVA) did not significantly 181	
influence the hematocrit (Figure 2A). To confirm vascular leakage by a secondary method, we 182	
injected Evans blue dye (EBD) 6h post-injection of either chymase or tryptase and, after an additional 183	
30 minutes, quantified the amounts of dye that leaked into the liver tissue (Supplemental Figure 2). 184	
EBD leaked significantly into the livers of mice that were tryptase-injected, confirming the induction of 185	
vascular leakage, while the increases in EBD in chymase-injected mice were not significant 186	
(Supplemental Figure 2). Thus, while both chymase and tryptase can impact vascular homeostasis, 187	
tryptase promoted the most substantial vascular leakage.   188	
Next we questioned whether the rise in hematocrit that occurred during tryptase/chymase 189	
treatment could result in hypovolemic shock. The standard way to measure infectious or anaphylactic 190	
shock in the mouse model is to record a drop in body temperature (39-41). To test this, mice were 191	
given 30ng of either tryptase, chymase or OVA i.v., followed by the measurement of temperature at 192	
regular intervals. Interestingly, both tryptase and chymase injections resulted in a dramatic drop in the 193	
body temperatures of mice, suggestive of a shock (Figure 2B). However, tryptase treatment resulted 194	
in a stronger drop in body temperature (~2.5°C below normal) compared to that of chymase treatment 195	
(~1.5°C) and persisted longer (Figure 2C). Control animals that were given essentially the same 196	
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medium in which proteins were diluted did not undergo any shock and only experienced a moderate 197	
and brief temperature decline that is likely attributable to the injection of saline, nor did animals that 198	
were injected with an equivalent amount of the exogenous protein, OVA (Figure 2B, C), which was 199	
used as a control for protein injection. Overall, these data show that, although both tryptase and 200	
chymase are able to cause plasma leakage in vivo, tryptase has a more profound effect on vascular 201	
endothelium with regards to inducing vascular leakage and shock, compared to chymase.   202	
 203	
Tryptase inhibition protects against DENV-induced hemoconcentration. 204	
 Based on the observation that tryptase is highly consequential to vascular leakage in DENV-205	
infected animals and sufficient to induce shock in vivo, we aimed to ameliorate vascular leakage in 206	
DENV-infected animals by therapeutically targeting tryptase. For this, we used the drug nafamostat 207	
mesylate since this drug is a highly specific inhibitor of tryptase at pico-molar concentrations and also 208	
approved for clinical use for intravascular coagulation (42, 43). Animals were treated with nafamostat 209	
mesylate after DENV infection and vascular leakage was measured in the animals by obtaining 210	
hematocrit readings.  We observed that nafamostat mesylate alone did not influence the hematocrit of 211	
healthy uninfected control animals. However, in DENV-infected animals where strong 212	
hemoconcentration indicating vascular leakage is observed during infection, nafamostat mesylate 213	
restored the hematocrit to homeostatic levels (Figure 3A). These data are further solidified by 214	
measurements of tryptase and chymase activities in the serum of mice from each experimental group. 215	
The enzymatic activities of both tryptase and chymase were significantly higher in the DENV-infected 216	
but vehicle-treated animals compared to that of control groups (both mock-infected vehicle-treated 217	
and mock infected drug-treated) (Figure 3B, Supplemental Figure 3). Treatment of DENV-infected 218	
animals with nafamostat mesylate resulted in functional serum tryptase levels that were at baseline, 219	
confirming the specific action of this drug in blocking tryptase activity in vivo (Figure 3B). Together, 220	
these data demonstrate that tryptase inhibition is able to therapeutically block DENV-induced plasma 221	
loss significantly. The specificity of the drug’s action on DENV-induced plasma leakage is further 222	
shown by the fact that nafamostat mesylate treatment did not alter chymase activity (Supplemental 223	
Figure 3) or ameliorate the drop in platelets that is observed during infection (Figure 3C) and did not 224	
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significantly influence the titers of virus in vivo (Figure 3D). Since tryptase can theoretically influence 225	
the coagulation and complement cascades(44, 45), we measured levels of complement component 226	
C3 in the serum of DENV-infected and vehicle- or nafamostat mesylate-treated animals but observed 227	
no changes in the levels of C3 with drug treatment, although C3 was reduced in DENV-infected 228	
animals compared to controls (Supplemental Figure 4), suggesting DENV induced a tryptase-229	
independent complement activation. These results support that the therapeutic effects of nafamostat 230	
mesylate on DENV-vascular leakage are due to its action as a specific inhibitor of tryptase enzymatic 231	
activity.  232	
We repeated our findings in a severe model of DENV viremia to establish whether vascular 233	
leakage could also be reversed in those mice. The AG129 mouse line is deficient in receptors for both 234	
Type-I and Type-II interferons and has been used extensively to study DENV infection in vivo. 235	
Nafamostat mesylate was effective in reducing hematocrit values in AG129 mice given both high and 236	
low inoculating doses of DENV (Figure 4A). Next, we evaluated if tryptase inhibition can also be 237	
effective in severe model of dengue disease, characterized by antibody-dependent enhanced 238	
infection (ADE) of DENV in AG129 mice. Mice were given an enhancing concentration of antibody 239	
4G2, followed by DENV infection, which, as expected, led to increased virus titers through ADE 240	
(Supplemental Figure 5). Subsequent to infection, mice were treated daily with the tryptase inhibitor 241	
nafamostat mesylate. Nafamostat mesylate treatment significantly reduced the hematocrit values on 242	
days 2 and 3 post-infection (Figure 4B), demonstrating that the tryptase-dependent mechanism for 243	
reducing vascular leakage is consistent in this second model that involves antibody-enhanced 244	
disease. We also measured the serum tryptase and chymase enzymatic activity in serum from each 245	
experimental group. Consistent with our data in WT mice (Figure 3B, Supplemental Figure 3) we 246	
observed that nafamostat mesylate treatment significantly reduced tryptase activity in AG129 mice on 247	
days 2 and 3 post-infection (Supplemental Figure 6A) yet had no effect on serum chymase activity 248	
(Supplemental Figure 6B), again confirming the specificity of this tryptase inhibitor. Finally, we 249	
examined the efficacy of delayed treatment, where AG129 mice infected with the same antibody-250	
enhanced strategy were treated with nafamostat mesylate daily, but beginning 24h after infection 251	
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(Figure 4C). Even with delayed treatment, nafamostat mesylate had a significant therapeutic effect 252	
and reduced hematocrit levels following infection (Figure 4C).  253	
 To confirm the influence of nafamostat mesylate on vascular leakage by an alternate method, 254	
we performed intra-vital multi-photon microscopy. The ears of AG129 mice that had been mock-255	
infected (Supplemental Video 1), infected with DENV in mice that were given vehicle control injections 256	
(Supplemental Video 2), or infected with DENV in mice that were given injections of nafamostat 257	
mesylate (Supplemental Video 3) were imaged after injection of FITC-dextran dye, which was used to 258	
visualize vascular leakage. Still images from various time points beginning 24h post-infection from 259	
Supplemental Videos 1-3 are presented in Figure 5A. While dye was confined to the blood vessels of 260	
control uninfected tissues for the duration of imaging, it can be visualized leaking into the tissue in 261	
DENV-infected animals (Figure 5A, Supplemental Videos 1-2).  Nafamostat mesylate treatment 262	
reversed the leakiness of the vasculature in DENV-infected animals (Figure 5A, Supplemental Video 263	
3). Quantification of the dye leakage in the videos showed DENV infection allowed dramatic increases 264	
in dye detection over the course of visualization while only a slight increase occurred in control 265	
uninfected tissues (Figure 5B). In contrast, fluorescence detection remained near baseline in DENV-266	
infected but nafamostat mesylate treated animals (Figure 5B). Additional experiments at 48h post-267	
infection for the same groups as described above confirmed the efficacy for nafamostat mesylate in 268	
blocking DENV vascular leakage (Supplemental Videos 4-6). These results further support tryptase as 269	
a mechanism of DENV-induced vascular leakage and also suggest this enzyme may be an effective 270	
therapeutic target.   271	
 272	
Tryptase levels correlate with DENV severity in humans. 273	
After experimentally establishing that both tryptase and chymase could negatively influence 274	
the integrity of the vascular endothelium during DENV infection and that they are sufficient to induce 275	
plasma leakage in mice, we did a retrospective study of acute human serum samples collected during 276	
an epidemic that occurred in Jakarta, Indonesia in 1975-1978(46-48). The 34 samples, from 277	
virologically confirmed DENV-infected patients, clinically graded to have a range of DENV pathologies 278	
from DF to fatal DHF (Figure 6A) and representing multiple serotypes (18% DENV-1, 24% DENV-3, 279	
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3% DENV-4 and 55% serotype undetermined), were blinded as to clinical severity of the patient and 280	
virus serotype. Consistent with our earlier published data (34), levels of chymase were significantly 281	
elevated in serum of patients with severe DENV outcomes, consistent with the clinical definition of 282	
DHF (Figure 6A). Remarkably, the levels of tryptase were also significantly elevated during DHF 283	
(Figure 6B). However, chymase levels showed a ~800% increase in DHF patients over DF patients, 284	
versus a 75% increase in tryptase for DHF patients over DF patients (Figure 6A-B). These findings 285	
are consistent with our previous report that chymase is a robust biomarker for DHF (34). Next, we 286	
assessed whether there was a correlation between the levels of tryptase or chymase with the severity 287	
of DHF (DHF grades II-IV and fatal DHF). DHF was graded according to the WHO guidelines(3). 288	
Interestingly, levels of tryptase followed a strong linear correlation with the severity of DHF in human 289	
patients (Figure 6C). However, although the levels of chymase were higher in DHF patients, there 290	
was no statistically significant correlation observed with the severity of DHF (R2=0.5, p=0.3, 291	
Supplemental Figure 7A). These data show that increased levels of serum tryptase were correlated 292	
with increased disease severity in patients (Figure 6B, C). To confirm this finding, a more recent 293	
cohort of serum samples prospectively collected in Sri Lanka in 2012-2013 were tested. These 294	
samples were previously shown to have significantly elevated chymase levels in DHF patients 295	
compared to DF patients(36). Consistent with findings in the Indonesian cohort, DHF patients 296	
compared to DF patients had significantly higher levels of serum tryptase (Figure 6D). Furthermore, 297	
tryptase levels (Figure 6E) but not chymase levels (Supplemental Figure 7B) were significantly 298	
correlated the grade of DHF. Collectively, these data suggest that tryptase is a mechanistic correlate 299	
of vascular leakage during severe dengue that could also potentially be used as a prognostic marker 300	
for DHF severity.  301	
 302	
Discussion 303	
Multiple theories have been put forward to explain how DENV vascular leakage syndrome is 304	
initiated and sustained in vivo. In the absence of strong and consistent evidence that endothelial cells 305	
are directly infected by DENV in humans, immune-mediated pathology is presumed to underlie the 306	
mechanism of increased endothelial permeability during DHF and DSS (2). In this work, we have 307	
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described a novel mechanism of vascular leakage during DENV disease and show that the MC-308	
derived protease, tryptase, is a host protein that is consequential for breaking endothelial tight 309	
junctions. Tryptase is a serene protease that functions in vivo to cleave a list of targets including 310	
kininogen, complement factor C3, clotting factor XII, fibrinogen, and others(49). Tryptase also 311	
regulates the activity of other serine proteases such as pro-urokinase, an important coagulation 312	
factor(50). Interestingly, an early report describing fatal DHF in the Philippines reported low levels of 313	
circulating fibrinogen accompanying intravascular coagulation (51), which would be consistent with 314	
degradation of this product by tryptase. Decreased serum fibrinogen, high levels of fibrinogen split 315	
products and intravascular coagulation were also observed subsequently in a cohort of patients from 316	
Thailand(52). Although it should be noted that intravascular coagulation is a rare outcome of 317	
dengue(52). Indeed, in our study, injection of tryptase alone was sufficient to induce shock in mice. A 318	
high affinity tryptase specific inhibitor, nafamostat mesylate, limited DENV-induced vascular leakage 319	
in vivo. This drug is currently approved for use to treat disseminated intravascular coagulation (42), 320	
which is also a potential clinical sign accompanying DSS (52-54). It is also effective for treatment of 321	
conditions where limiting endothelial activation and coagulation are beneficial, such as renal ischemia 322	
reperfusion injury(55, 56). While nafamostat mesylate can inhibit some other serine proteases at high 323	
concentration, it has been shown to be highly specific for tryptase at the concentrations used in this 324	
study(57-59). Some additional pathways that can be influenced directly or indirectly by tryptase 325	
include PAR receptors and the fibrinolytic systems(38, 44, 50), as previously discussed, as well as the 326	
kallikrien-kinin system and complement activation pathways(45, 60). Tryptase is also a known 327	
glycocalyx sheddase(61) and glycocalyx degradation has been observed to occur during human 328	
dengue infection(62, 63). Although not tested here, the tryptase-dependent effect of nafamostat 329	
mesylate on coagulation factors such as fibrinogen(64, 65), could potentially be an added advantage 330	
for the treatment of severe DENV disease since fibrin split products and intravascular coagulation are 331	
known to occur during DHF/DSS. 332	
Importantly, nafamostat mesylate was effective in multiple models of DENV infection, including 333	
immunocompetent and immunocompromised mice and antibody-enhanced models of severe DENV 334	
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disease. We also observed efficacy with delayed treatment. Antibody-enhancement is thought to 335	
promote severe disease due to antibody-dependent uptake of virus particles by Fc receptor-bearing 336	
cells and we have recently shown that FcR-dependent enhancement of MC degranulation occurs as a 337	
second antibody-dependent mechanism leading to enhanced vascular leakage(35). In humans, 338	
biomarkers of MC activation such as chymase are detected at higher levels in patients with secondary 339	
infection, supporting that enhanced MC degranulation occurs during secondary DENV infection(34), 340	
which could be a factor in the efficacy of nafamostat mesylate in the animal model of antibody-341	
enhanced severe disease in addition to the possibility of increased activation of MCs due to higher 342	
titer of virus resulting from traditional ADE. Aside from antibody-enhanced degranulation, traditional 343	
ADE can allow MCs to become infected, which could augment production of transcriptionally activated 344	
inflammatory mediators, such as cytokines, further during secondary infection(66). In human serum 345	
samples examined from 2 independent cohorts of patients with severe disease, we show that the 346	
levels of tryptase are significantly correlated with the grades of DHF in DENV patients. Our results 347	
emphasize the role of tryptase in DENV-induced vascular permeability and raise the possibility of it 348	
being a novel therapeutic target in treating severe dengue patients at risk for hemorrhage and shock.  349	
We have previously demonstrated that MCs induce vascular leakage during DENV infection in 350	
animal models (34, 35). However, the mechanisms of action of MC products on the vasculature and 351	
the mediators involved in vascular permeability in this context were previously unknown. MCs can 352	
release a multitude of soluble mediators (lipids, cytokines, chemokines and growth factors) as well as 353	
particulate mediators in the form of exocytosed granules. These granule structures are known to 354	
contain many vasoactive and immune modulatory products such as proteases, histamine, heparin, 355	
TNF, anti-microbial peptides and others (23). To begin to address which of these many mediators 356	
contributes most substantially to DENV vascular leakage, we fractionated the products released by 357	
DENV-activated MCs in to soluble and particulate fractions and applied them to endothelial 358	
monolayers. Serum from DENV patients is also sufficient to induce break down of tight junctions of 359	
endothelial monolayers ex vivo (67). Our TER measurements of these huMEC monolayers revealed 360	
that the MC granule associated products, and not the soluble mediators, disrupted endothelial 361	
monolayer integrity severely. The dominant MC proteases, tryptase and chymase, constitute the 362	
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majority of the proteins that are contained within granules. Expression of tryptase and chymase are 363	
unique to MCs and their roles in viral pathogenesis are unknown. Chymase is best recognized as an 364	
angiotensin-converting enzyme, but it also can influence the vasculature in several ways. For 365	
example, chymase is thought to degrade some extracellular matrix components and has been shown 366	
to cleave Endothelin-1, promoting vasoconstriction (68). We also recently showed that chymase is 367	
important for inducing permeability at the blood brain barrier during JEV infection(69). Tryptase is 368	
known to have a more profound and direct influence on peripheral vascular permeability by cleaving 369	
PAR receptors at the inter-endothelial junctions(38). Interestingly, using recombinant purified 370	
chymase and tryptase we show here that exposure of endothelial monolayers to tryptase breaks 371	
endothelial tight junctions in a dose dependent manner. This was further verified by injecting tryptase 372	
in vivo, which was sufficient to reduce expression of the adhesion molecule CD31 on vascular 373	
endothelium and to induce vascular leakage and shock in mice. Although to a lesser extent at the 374	
concentration given, chymase was also able to induce moderately increased hematocrit levels that 375	
were not accompanied by significantly increased leakage of EBD into tissues at the time point 376	
assessed. The influence of chymase on hematocrit levels here could potentially be through its 377	
function to degrade the extracellular matrix(70). The effects of chymase on endothelium could be 378	
compounded by the presence of TNF, which is also contained within MC granules(30) and, 379	
furthermore, thought to be a possible contributing factor to DENV-induced immune pathology(6).  380	
Notwithstanding these observations, there are other factors that are thought to contribute to 381	
vascular permeability during DENV infection. One such host molecule already discussed is TNF, 382	
which is not only pre-stored within MC granules, but also produced abundantly by cells that are 383	
infected by DENV. Some studies have shown that TNF blockade can limit vascular pathology and 384	
promote survival of DENV-infected animals(6). However, most studies implicating TNF experimentally 385	
were performed in mice that are immunocompromised and lacking the IFN-response system (6). This 386	
experimental system has the potential to over-emphasize the virus replication-dependent aspects of 387	
vascular permeability and may result in replication of virus within cell types that would be resistant to 388	
infection in IFN-competent animals (2). Recent studies have shown that A129 mice, which are 389	
deficient in receptors for Type-I interferons, are susceptible to maternal antibody-enhanced lethal 390	
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DENV infection that is TNF-dependent, without showing significantly increased levels of vascular 391	
leakage (71). Moreover, in human studies, TNF could not be consistently linked to DENV severity (2, 392	
72). Recently, DENV NS1 protein has also been implicated in vascular leakage in IFN-deficient 393	
mouse models (13). Although NS1 may contribute to vascular permeability, further studies are needed 394	
to reconcile the observations of some studies that NS1 levels cannot be correlated with severe 395	
disease (14-18), including further attempts to control for the potential of antibodies to influence the 396	
kinetics of host clearance of NS1 and/or detection of the NS1 protein in the serum. MC degranulation 397	
in response to DENV is also dose-dependent; thus, higher levels of DENV should also promote 398	
heightened degranulation responses but the reactivity of individual patients to unique amounts of viral 399	
antigen could still vary. Identification of MCs as a potential source of vasoactive factors also opens the 400	
possibility of additional host-associated factors that influence MC function which might also then 401	
influence DENV disease severity, such as the patient’s allergic state, commensal microflora (including 402	
parasitic infections), exposure to allergy medications, homeostatic mechanisms for protease inhibition 403	
and genetic factors governing MC activation and distribution in vivo.  404	
Since MC proteases are pre-synthesized and some of these enzymes are stored within MCs, 405	
exclusively, this might also explain why many studies that have attempted to interrogate the pathways 406	
involved in DENV-induced vascular leakage through transcriptional profiling or by examining the 407	
responses of various infected cell types have not identified increased tryptase or chymase to be 408	
associated with DENV infection. We have previously reported that the MC protease, chymase, is a 409	
biomarker of disease severity and present in the serum of DHF patients at levels ~10-fold that of DF 410	
patients(34). Consistent results were observed in this study, examining cohorts of patients from 411	
Indonesia and Sri Lanka. In this case, both chymase and tryptase were elevated in the serum of DHF 412	
patients.  While chymase may be a more precise biomarker of MC activation during DENV infection, 413	
our data shows that tryptase is mechanistically more consequential for leakage and shock. We think 414	
that this difference could be partially attributed to the difference in functional stability of these proteins 415	
in the circulation. The functional half-life of tryptase in the plasma is ~8min, which is further stabilized 416	
in the presence of heparin for ~2h(73). Chymase, in contrast, is very sensitive to the presence of 417	
protease inhibitors present in the plasma, such as secretory leukocyte proteinase inhibitor (SLPI)(74), 418	
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which could reduce chymase activity in spite of having high circulating protein levels. Furthermore, in 419	
contrast to tryptase, SLPI activity is greatly enhanced in the presence of heparin, which was shown to 420	
limit the functional half-life of chymase to 0.5sec (74). This is consistent with the observation that 421	
injection of high levels tryptase led to a more prolonged drop in temperature in animals, while an 422	
equivalent concentration of chymase resulted in only a transient temperature drop. We believe that 423	
even though both tryptase and chymase are fairly stable proteins structurally, the differences in their 424	
functional enzymatic stability could explain why tryptase is a more potent inducer of endothelial 425	
dysfunction during severe DENV disease. Since human MCs display heterogeneity based on their 426	
tryptase and chymase content, the types of MCs that are activated might play a role in the severity of 427	
disease. While all mature human MCs are thought to contain tryptase within their granules, some MCs 428	
have nearly undetectable levels of chymase(75).  429	
Our results also do not suggest that MC proteases must act alone in their ability to induce 430	
vascular leakage during DENV infection. We believe that other factors that are produced both by MCs 431	
and also by independent lineages of cells (particularly those experiencing viral replication) are likely to 432	
contribute to vascular leakage. It is important to note that patients with mild DENV infections display 433	
signs of microvascular permeability such as bruising, purpura, and edema (2). This is also the case 434	
during the acute phase of disease for those who subsequently develop severe complications. Another 435	
unknown is the role of the strain of DENV in activating MCs.  It is known that different strains may 436	
have variable infectivity for target cells, which may influence transmission dynamics and virulence. 437	
Nevertheless, MCs may be key for initiating the substantial vascular leakage that is characterized by 438	
severe DENV infection through their ability to degranulate in response to DENV and the ability of their 439	
product, tryptase, a dominant MC granule component, to cleave PAR receptors at endothelial 440	
junctions and to induce shock.   441	
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Materials and Methods 442	
Cell lines, virus strains and culture conditions 443	
The huMEC primary cell line HMVEC-d Ad-Dermal MV Endo Cells (Lonza, CC2543) was maintained 444	
in EGM-2MV BulletKit media (Lonza, CC3202). The human clinical isolate of DENV2, strain Eden2, 445	
which was obtained from the Early Dengue Infection and Outcomes Study (Eden)(76), was 446	
maintained at low passage as previously described (24, 34).  447	
 448	
Measurement of endothelial activation and permeability 449	
huMECs were grown in 3µm inserts (BD Biosciences) inside 24-well plates for 4-5 days to form a 450	
monolayer.  huMECS were then incubated for 24h with different concentrations of either tryptase or 451	
chymase (1µM, 0.1µM, 0.01µM, or 0.001µM). Monolayer permeability was measured by acquiring 452	
TER readings at baseline (t=0) and 24h after treatment with tryptase, chymase, MC supernatants or 453	
appropriate controls. Human ROSA MCs (3X106 cells)(77), a gift from Michel Arock (Ecole Normale 454	
Supérieure de Cachan, Cachan, France) were treated for 1h with either DENV (MOI 1) or control 455	
media (untreated), after which, the cellular fraction was removed by two rounds of centrifugation at 456	
500xg for 5 min. The particles were then pelleted from whole supernatant by spinning at 12,000xg for 457	
10 min at 4°C. Soluble fractions were collected and particles were washed and resuspended in 458	
maintenance media, followed by exposing them to huMECs monolayers. TER readings were obtained 459	
using the Millipore Millicell-ERS (Electrical Resistance System).  460	
 461	
Immunofluorescence assay 462	
huMECs were grown on coverslips (Warner Instruments) inside 24-well plates for 2-4 days to form a 463	
monolayer.  huMECS were then incubated with various concentrations of tryptase or chymase (1µM 464	
or 0.1µM). Treated huMECs were incubated for 24h, followed by fixing with paraformaldehyde. 465	
Coverslips were then washed with PBS and blocked using 0.1% saponin in 1% BSA in PBS 466	
(permeabilizing buffer). Primary antibodies against α-tubulin (GeneTex, GTX11302) and ZO-1 467	
(Invitrogen, 402200) were added to permeabilization buffer and incubated overnight followed by 468	
washing using permeabilizing buffer. Next, the secondary antibodies, anti-mouse-conjugated FITC 469	
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(Jackson ImmunoResearch, 115-096-006) and anti-rabbit-conjugated AlexaFlour660 (ThermoFisher 470	
Scientific, A21073) were added in permeabilizing buffer and incubated for 2-4h. Finally, coverslips 471	
were mounted using Pro-Long Gold Anti-fade reagent containing DAPI (Invitrogen, P36931). Cell 472	
images were obtained using the LSM710 Carl Zeiss Confocal Microscope using a 63x objective lens.  473	
 474	
Cloning and purification of MC proteases 475	
The RNA was isolated from huMCs using RNeasy Mini Kit (Qiagen) and cDNA was made using cDNA 476	
synthesis kit (Bio-Rad). For chymase, PCR amplification was performed with the following primers: 477	
5´–CGG CTC ATA TGA TGC TGC TTC TTC CTC TC–3´ and 5´–ATA CTC TCG AGT TAA TTT GCC 478	
TGC AGG ATC TG–3´, where the underlined sequence corresponds with Nde I and Xho I restriction 479	
sites. For tryptase, PCR amplification was performed with the following primers:  5´–AGT CTC ATA 480	
TGA TGC TGA GCC TGC TGC TGC TGG CG–3´ and 5´–CAA TGA AGC TTT CAC GGC TTT TTG 481	
GGG ACT AGT GGT–3´, where the underlined sequence corresponds with Nde I and Hind III 482	
restriction sites. PCR products were subsequently cloned in the pET28a Vector (Novagen) using the 483	
restriction sites included within the amplification primers. The recombinant pET28a vectors containing 484	
either human tryptase or chymase were sequenced to verify in-frame insertion. Recombinant pET28a 485	
plasmids were then transformed into E. coli BL-21 (DE3) cells, which were grown in LB broth 486	
containing Kanamycin (50µg/ml) at 37°C until an OD-600 of 0.4-0.6 was reached. Protein expression 487	
was then induced with 1mM IPTG, overnight at 16°C. Cell lysates were sonicated and clarified 488	
supernatant was loaded into HisTrap columns (GE healthcare). HPLC purification was performed 489	
according to the manufacturer’s instructions under Hybrid conditions using an AKTA machine (GE 490	
Healthcare). Recombinant active human chymase (CSB-YP005599HU) and tryptase (CSB-491	
YP024128HU) expressed in yeast were purchased from CUSABIO, USA. Catalytic active sites are 492	
highly conserved among human and mouse tryptase and chymase and, therefore, these proteins are 493	
functionally active in vivo(78). 494	
 495	
Mouse experiments 496	
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Wild type mice on a C57BL/6 background were purchased from InVivos and AG129 mice, originally 497	
purchased from B&K Universal, UK, were a gift from Sylvie Alonso (NUS, Singapore). For all strains, 498	
6-8 weeks old female mice were used for experiments. All experiments were performed according to 499	
protocols approved by the SingHealth Institutional Animal Care and Use Committee. For in vivo 500	
studies, due to the large amounts of protein required, yeast-produced MC proteases were purchased 501	
from CUSABIO, USA and OVA was purchased from Sigma. Mice were administered chymase, 502	
tryptase or OVA in PBS via tail vein injection at the concentrations provided in the figure legends. 503	
Blood was collected 6h post-injection and hematocrit values were acquired using an AcT Diff 504	
automated hematology analyzer (Beckman Coulter). For experiments involving flow cytometry to 505	
assess endothelial cells ex vivo 100ng of chymase or tryptase or 1X106 PFU of DENV was given by 506	
subcutaneous injection in the mouse footpads. Shock was measured quantitatively in mice by 507	
recording the temperature at regular intervals using a rectal probe after injection of 30ng of chymase 508	
or tryptase by tail vein. For drug studies, nafamostat mesylate (Sigma, N0289) was given to mice 509	
(0.06 or 0.6 mg/kg) daily i.p. in a 50µl volume of saline and saline alone served as the vehicle for 510	
controls, beginning 1h or 24h post-infection, as indicated in figure legends. Hematocrit and platelet 511	
readings were obtained from whole blood collect via cheek-vein, using an automatic hematology 512	
machine at indicated time points of 24h, 48h or 72h. Virus quantification was performed after RNA 513	
isolation from the spleen at 24h, 48h or 72h post-infection. cDNA was synthesized from 1µg of RNA 514	
using the iScript cDNA Synthesis Kit (Bio-Rad) with the addition of primer 5′-TTG CAC CAA CAG TCA 515	
ATG TCT TCA GGT TC-3′ to synthesize viral RNA to cDNA. Real-time PCR was performed using 516	
SYBR Green reagent (Biorad) and the following DENV2 primers: forward, 5′- TCA ATA TGC TGA 517	
AAC GCG CGA GAA ACC G -3′; reverse, 5′- CGC CAC AAG GGC CAT GAA CAG -3′. Systemic 518	
infection in AG129 mice was achieved by injecting 1x106 or 5x107 PFU of DENV via the i.p. route. For 519	
the severe DENV infection model of antibody-dependent enhancement, AG129 mice were passively 520	
given 50µg/mouse of an antibody 4G2, followed by infection with a high dose (1x108 PFU) of DENV i.p 521	
after 24h, according to a published protocol (79). Mice were treated with 0.6 mg/kg of nafamostat 522	
mesylate at 24h intervals.  523	
 524	
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Intra-vital microscopy 525	
AG129 mice were infected with 1X106 PFU DENV by i.p. injection. Mice were either mock treated with 526	
vehicle or treated with nafamostat mesylate (0.6 mg/kg), 1h prior to infection or 24h post-infection. 527	
Mice were anesthetized and injected with 100µl of 50mg/ml 70KDa FITC-Dextran (Sigma, 46945) (80) 528	
and two-photon images of the mouse ears were acquired using a Bergamo® II Series Multiphoton 529	
Microscopes from Thorlabs (NJ, USA) 5 minutes post-FITC-dextran injection every 2 sec for 18 530	
minutes (920 nm laser), as described previously(81). For quantifying vascular leakage, 10 areas of 531	
equal size were marked near blood vessels and the fluorescence intensity was measured using 532	
FIJI(82) and mean fluorescence intensity for each time point were plotted using GraphPad Prism. 533	
Images were converted to videos using FIJI (NIH). Videos are representative of 3 experiments.  534	
 535	
Measurement of chymase activity, tryptase activity and complement C3 in mouse serum 536	
Functional serum tryptase and chymase activities were measured by using Mast cell degranulation 537	
assay kit (Millipore, IMM001) and chymase activity assay kit (Sigma-Aldrich, CS1140) respectively. 538	
Following manufacturer instructions, the reaction was carried out in a total volume of 100µl using 5µl 539	
of serum and then relative chymase and tryptase activity was calculated by normalizing the values to 540	
chymase and tryptase activity in serum of mock-infected mice. Complement C3 concentrations in 541	
serum were measured using Mouse Complement C3 ELISA kit (Abcam, ab157711) with a minimum 542	
detection range of 3.13ng/ml to 200ng/ml. Serum samples were diluted 1:50,000 times according to 543	
the manufacturer’s instructions and 100µl of diluted serum was used for the assay. 544	
 545	
Detection of MC proteases in clinical samples 546	
Human clinical samples were collected from hospitalized patients as part of surveillance for severe 547	
dengue in Jakarta, Indonesia from 1975-1978 (46-48). Other than for an unknown period in the 1990s 548	
when a freezer failed and the samples thawed, they were maintained at -60 to -80 C for the four 549	
decades of storage by one of us (DJG). The DHF grade was retrospectively classified according to 550	
the 1997 WHO classification criteria(3). For the second Sri Lankan cohort, human clinical samples 551	
were prospectively obtained by the Ministry of Health in Sri Lanka and provided by the Dengue Tools 552	
	 22 
Project(83, 84). Dengue Tools recruited patients with undifferentiated febrile illness with a duration 553	
less than 7 days, and serum samples were selected for this study based on being confirmed dengue-554	
positive using previously described methods(84).  All patients provided blood samples with informed 555	
consent. Dengue Tools serum samples collected at the time of patient recruitment were selected for 556	
tryptase testing based on having had fever <6 days, a clear discharge diagnosis of either DF or DHF, 557	
and having sufficient remaining serum to perform the test. Classification was also determined based 558	
on the 1997 WHO criteria(3). Serum was stored at -80°C. Ethical approval was obtained from the 559	
Ethics Review Committee, Faculty of Medicine, University of Colombo, Sri Lanka and the Institutional 560	
Review Board, National University of Singapore, Singapore. All DHF patients met the WHO case 561	
classification for Grades I, II, III or IV(3). ELISAs for human chymase (Blue Gene, E01M0368) and 562	
human tryptase (Cloud-clone Corp, SEB070Hu) were performed on blinded samples according to 563	
manufacturer’s instructions and un-blinded only after analysis.  564	
 565	
Statistics 566	
Prism 7 and Excel were used to determine statistical significance and SPSS was used to verify that 567	
the input-data were normally distributed using the Shapiro-Wilk test prior to analysis using parametric 568	
tests. Violin plots were generated using a web-based tool(85). Where appropriate for direct 569	
comparisons of two samples, Student’s un-paired t-test was used. For multiple groups, 1- or 2-way 570	
ANOVAs were performed with post-tests to determine between-groups statistical significance or 571	
regression analysis in the case of human biomarker data. Data were considered significant at p≤0.05. 572	
The numbers of biological or technical replicates for each group are indicated in each figure legend.  573	
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Figure 1: Tryptase and chymase break tight junctions to disrupt endothelial cell contact sites 
(A) DENV stimulated MC supernatant was transferred onto huMEC monolayers or separated into soluble 
and particulate fractions, followed by transfer onto huMEC monolayers. For controls DENV alone or media 
alone groups were used. TER of huMEC monolayers was measured 24h after treatment. Whole supernatant 
or isolated MC-particles each significantly reduced the TER of huMEC monolayers (p<0.05 by 1-way 
ANOVA with Dunnett’s post-test). (B-C) TER of huMEC monolayers after treatment for 24h with either 
purified, recombinant tryptase (B) or chymase (C). For A-C, * indicates a significant decrease in TER over 
controls by 1-way ANOVA with Dunnett’s post-test (p<0.05). (D-F) huMECs were treated with low (0.1µM) or 
high (1µM) concentrations of either tryptase or chymase for 24h, followed by fixation and staining against 
tubulin, green; nuclei, DAPI and tight junctions (ZO-1, red). (D) In control cells tight junctions were intact in 
between cells, visualized by ZO-1 staining. (E) Tryptase induced a concentration-dependent reduction in 
ZO-1 staining that appeared disjunctive at low concentration and absent at high concentration. Lifting of 
cells forming gaps was also observed after high concentration tryptase treatment.  (F) Low concentration 
chymase had no apparent effect on tight junctions, while staining grew more punctate at high concentration. 
For A-F, data are representative of 3 independent repeats. For D-F, scale bar=25µm. (G-H) Levels of CD31 
on endothelial cells were measured by flow cytometry on cells isolated from mouse footpads 6h after 
injection of 100ng of tryptase, chymase or saline vehicle control. (G) CD31+ cells showed reduced levels of 
its staining after injection of tryptase (representative histogram plots). (H) Comparison of mean fluorescence 
intensity (MFI) of CD31 staining in mouse footpads (n=5-6 each group) showed that tryptase, but not 
chymase, is sufficient to induce a significant decrease in CD31 staining in vivo (right panel, p<0.05 by 1-
ANOVA with Dunnett’s post-test). For graphs, error bars represent the SEM.  
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Figure 2: Mast cell proteases promote vascular leakage and shock in vivo  
(A) Hematocrit values were obtained 6h after injection with saline alone or 30ng of either tryptase, chymase 
or OVA. Means differ significantly by 1-way ANOVA (p<0.0001). Bonferroni’s multiple comparison test was 
used to determine significance amongst groups. For control n=15, for tryptase and chymase n=10 and for 
OVA n=5. Data were added from two independent experiments. (B-C) Mice (n=3-4) were injected with 30ng 
each of tryptase, chymase, or OVA by the i.v. route or an equivalent volume of saline was injected for 
controls. To measure shock, the body temperature of animals was recorded at every 5min for the first 15 
min and subsequently at 10min intervals. (B) Both tryptase and chymase caused sudden drop in body 
temperature, indicative of shock, compared to both OVA and saline control groups. Data were analyzed by 
2-way ANOVA with Holm-Sidak’s multiple comparison test to compare temperatures at each time point (C) 
The maximal difference in temperature during the time course is presented, suggesting that tryptase 
treatment causes significantly higher plasma loss in animals compared to chymase, OVA and saline control 
groups, determined by 1-way ANOVA with Holm-Sidak’s multiple comparison test. For all panels, the mean 
with error bars representing the SEM are presented and significance is indicated by **** for p<0.0001, *** for 
p<0.001, ** for p<0.01 and * for p<0.05.   
 
	 32 
 
 
Figure 3: Tryptase inhibition therapeutically blocks vascular leakage during DENV infection 
Mice (n=3-5 per group) were either mock-infected or infected with DENV (1x106 PFU) followed by treatment 
with vehicle control (saline) or using a specific tryptase inhibitor, nafamostat mesylate at a dose of 
0.06mg/kg. (A) Hematocrit analysis was performed using an automated hematology analyzer on whole 
blood at 24h post-treatment. (B) Serum was isolated to measure tryptase activity by enzymatic assay. Only 
DENV-infected mice that were vehicle-treated had elevated tryptase activity over uninfected control group. 
Nafamostat mesylate treatment reversed tryptase activity to baseline levels. (C) Platelet counts at 24h are 
presented. The data show a strong reduction in DENV-induced vascular leakage upon treatment with 
tryptase inhibitor, nafamostat mesylate, but no significant (ns) difference in platelet counts compared to 
DENV-infected and vehicle treated mice. For A-C statistical significance was determined using 1-way 
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ANOVA with Bonferroni’s multiple comparison test. (D) No difference in the DENV burden in the spleen 
determined by real time RT-PCR was observed between vehicle and nafamostat mesylate treated animals 
at 72h post-infection by Student’s un-paired t-test. For all panels, the mean with error bars representing the 
SEM are presented and significance is indicated by **** for p<0.0001 and * for p<0.05.  
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Figure 4. Improvement of vascular leakage in severe DENV infection models 
AG129 mice were infected with a low (1x106 PFU) or a high (5x107 PFU) dose of DENV and either mock or 
nafamostat mesylate treated beginning 1h post-infection. Uninfected n=3, DENV infected vehicle treated 
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n=4-5 and DENV infected nafamostat mesylate treated n=4-5) (A) At 24h post-infection, hematocrit was 
measured. A single treatment of nafamostat mesylate reversed DENV-induced vascular leakage for both 
infection doses. (B-C) Nafamostat mesylate effectively restored hematocrit values to baseline levels at days 
2 and 3 post-infection in an antibody-enhanced DENV mouse model. Treatment was initiated (B) 1h or 
delayed (C) 24h post-infection and given at 24h intervals thereafter. Statistical significance was calculated 
using 1-way ANOVA with Bonferroni’s multiple comparison test and is indicated by **** for p<0.0001, *** for 
p<0.001, ** for p<0.01 and * for p<0.05. For all graphs, the mean with error bars representing the SEM are 
presented.  
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Figure 5. Visualization of inhibition of plasma leakage in DENV-infected mice 
AG129 mice were infected with 1x106 PFU of DENV by i.p. and either treated with nafamostat mesylate or 
with vehicle. Mice (n=3), 24h post-infection, were injected with 70KDa FITC-Dextran. Two-photon images 
were acquired continuously at 2 sec intervals, beginning 5 min post-injection, for 18 min total. (A) 
Representative images from the indicated time points post-FITC-dextran injection from Supplemental 
Videos 1-3, showing vascular leakage in the DENV-infected mock-treated ear, while control mice and 
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DENV-infected mice treated with nafamostat mesylate showed no visually discernible vascular leakage. 
Scale bar=50µm (B) The mean fluorescence intensity in the acquired images over time is presented. 
Intensity was measured by averaging 10 areas in the interstitial space. Data are representative of 3 
independent experiments.  
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Figure 6. Serum tryptase levels are correlated with DHF/DSS in humans 
Serum samples from virologically confirmed hospitalized dengue patients in Jakarta, Indonesia in 1975-78 
(n=9 DF and n=25 DHF), were tested retrospectively in a blinded manner for (A) chymase and (B) tryptase. 
Both were significantly increased (p<0.0001 and p=0.0004, respectively, determined by Student’s un-paired 
t-test) in patients with DHF compared to DF.  (C) Mean serum tryptase levels for each grade of DHF were 
also strongly correlated with the grade of DHF based on the patient’s reported symptoms; p=0.05; R2=0.89. 
(D-E) Tryptase was measured in a second cohort of prospectively obtained patient samples from 
virologically confirmed dengue patients (n=30 DF and n=25 DHF) in Sri Lanka, Colombo in 2012-2013. (D) 
Serum tryptase levels were significantly elevated in serum samples from DHF vs DF patients (p=0.0005). 
(E) Mean serum tryptase levels in Sri Lankan samples were strongly correlated with disease severity; 
p=0.02; R2=0.86. For all graphs, the mean with error bars representing the SEM are presented. 
